

# Development of a universal CTL-based vaccine for influenza

Diego E. Cargnelutti,<sup>1</sup> María V. Sánchez,<sup>1</sup> Nora M. Mattion<sup>2</sup> and Eduardo A. Scodeller<sup>1,\*</sup>

<sup>1</sup>Institute of Experimental Medicine and Biology of Cuyo (IMBECU- CONICET); Mendoza, Argentina; <sup>2</sup>Animal Virology Center; Institute of Science and Technology Dr. César Milstein; CONICET; Buenos Aires, Argentina

**Keywords:** Influenza vaccines, cellular immunity, cytotoxic-T-lymphocytes, recombinant antigen, cross-presentation, adjuvants

In pursuit of better influenza vaccines, many strategies are being studied worldwide. An attractive alternative is the generation of a broadly cross-reactive vaccine based on the induction of cytotoxic T-lymphocytes (CTL) directed against conserved internal antigens of influenza A virus. The feasibility of this approach using recombinant viral vectors has recently been demonstrated in mice and humans by several research groups. However, similar results might also be achieved through immunization with viral proteins expressed in a prokaryotic system formulated with the appropriate adjuvants and delivery systems. This approach would be much simpler and less expensive. Recent results from several laboratories seem to confirm this is as a valid option to be considered.

## Control of Seasonal and Pandemic Influenza

Seasonal influenza is an acute respiratory illness caused by influenza virus. This disease has a strong impact on public health worldwide causing, annually, 3 to 5 million cases of severe illness and between 250,000 and 500,000 deaths, mainly among children, elderly and immune-suppressed individuals (<http://www.who.int/mediacentre/factsheets/fs211/en/>). The best way to fight the impact of this disease is to vaccinate the population. Available vaccines are mostly inactivated ones, with a smaller proportion of live attenuated vaccines. Inactivated vaccines are produced mainly in embryonated chicken eggs and to a lesser extent in cell culture.<sup>1,2</sup> Influenza vaccines induce protection in immunized individuals through the generation of neutralizing antibodies, mainly directed against the viral envelope glycoprotein hemagglutinin (HA). Virus antigenic variants arise constantly due to the high variability of the gene encoding the HA. Given the high rate of antigenic variation of the HA, antibodies that neutralize a subtype are often ineffective to neutralize other subtypes, and consequently the strains included in seasonal vaccines must be constantly updated. Vaccine efficiency severely diminishes when new strains emerge with antigenic changes in the virus envelope proteins, and situations where the antigenic matching between vaccine strains and the new circulating ones

is sub-optimal are not exceptional. On rare occasions, completely new pandemic influenza variants arise, to which most of the human population has not been exposed. Under these circumstances, population immunity is low or null, allowing for an accelerated transmission of the new strain worldwide, which can have devastating consequences in terms of human lives. A recent analysis of the effectiveness of influenza vaccines holds that the immunity generated during certain seasons is at best moderate, when not significantly low or absent. In the ideal situation when antigenic matching between vaccines and circulating strains is optimal, average effectiveness was 69%.<sup>3</sup> During an outbreak of a pandemic strain there is a risk that the development of a vaccine for the emerging strain be too slow and, when available, come too late.

## Improving the Performance of Current Vaccines

Much effort has been devoted to the improvement of current vaccines using different strategies, such as exploring new routes of vaccine administration, like oral,<sup>4</sup> intranasal,<sup>5</sup> or intradermal immunization,<sup>6</sup> new delivery systems like micro-needles<sup>7</sup> or addition of adjuvants which might allow for an increase in the humoral and cellular responses,<sup>8,9</sup> and a significant decrease in the dose of protective antigen needed.<sup>10</sup> It has also been reported that variations in the method of inactivation can significantly improve vaccine efficacy.<sup>11,12</sup>

## Development of New Generation Vaccines

The main line of work in this field is focused on generating totally new vaccines using genetic engineering techniques. Conspicuous examples of this are: expression of the viral HA by means of recombinant vectors,<sup>13-15</sup> production of virus-like particles (VLP) of influenza containing the influenza proteins HA and Matrix1 (M1),<sup>16</sup> production of recombinant HA subunit vaccines in insect cells through the baculovirus system,<sup>17</sup> and production of recombinant HA or its fusion with flagellin in *Escherichia coli*.<sup>18,19</sup> DNA vaccines and peptide based vaccines have already been assayed in humans with promising results.<sup>20,21</sup> While many of these strategies proved to be very efficient and in some cases induced significant increases in cross-reactive immune responses, they did not completely solve the problems derived from the high antigenic variability of influenza virus.

\*Correspondence to: Eduardo Alberto Scodeller; Email: [Eduardo\\_scodeller@hotmail.com](mailto:Eduardo_scodeller@hotmail.com)

Submitted: 10/11/12; Revised: 12/27/12; Accepted: 01/10/13  
<http://dx.doi.org/10.4161/bioe.23573>

## A Universal Vaccine for Influenza

This line of work is pursuing a “universal” type of vaccine, that is, a vaccine that can protect against almost all known subtypes of influenza, including pandemic strains.<sup>22</sup> In this regard three main strategies are being pursued:

**Induction of neutralizing antibodies against highly conserved regions of the HA.** The dogma that the influenza virus neutralization is mediated only by antibodies that bind to the globular head of the HA protein has been recently challenged. Several laboratories worldwide have generated broad spectrum human monoclonal antibodies capable of neutralizing the virus by binding to a highly conserved region of the HA (the stem or stalk domain).<sup>23</sup> Some of these monoclonal antibodies are capable of reacting with all the known specificities of HA, and it has been demonstrated that passive transfer of this kind of antibodies to mice and ferrets may protect against a challenge with heterologous strains.<sup>24</sup> However, it is difficult to find the appropriate antigen capable of efficiently inducing such antibodies *in vivo* after immunization.<sup>25</sup>

**An influenza A vaccine based on the ectodomain of the Matrix2 protein.** The M2 protein (encoded in the same gene as the M1 protein) is a tetramer, functioning as an ion channel, and is present in very low amounts on the viral particle surface. The N-terminus of this protein (known as ectodomain or M2e) is highly conserved among strains of almost any origin. Based on this, M2e has been postulated as a very good candidate for the development of a universal vaccine. This assumption has been thoroughly demonstrated in pre-clinical models using various strategies.<sup>26,27</sup> It was demonstrated that alveolar macrophages and Fc-receptors are fundamental for anti-M2e IgGs-mediated protection to occur.<sup>28</sup> Currently, the potential of an M2e-based universal vaccine is also being analyzed in human clinical trials.<sup>29,30</sup> Although a vaccine based on the induction of anti-M2e antibodies is very promising, it will probably need to be combined with other conserved influenza antigens, able to elicit an adequate cellular response for a fully protective immunity.

**A T-cell vaccine for influenza.** The goal of a T-cell vaccine is to induce a strong response of specific CD4<sup>+</sup> and CD8<sup>+</sup> lymphocytes which may contribute to pathogen clearance by recognition and elimination of infected cells. For several important human infectious diseases, the efficacy of T-cells to induce therapeutic or prophylactic vaccines based on the use of replication-deficient viral vectors has already been established.<sup>31</sup> In the particular case of influenza, the generation of a non-sterilizing cellular based immunity is being sought; an immunity which would substantially decrease morbidity and mortality induced by the infection. Cytotoxic T-lymphocytes (CTL) are very effective in killing target cells by different mechanisms, thus eliminating the viruses from the infected organisms. In the case of influenza, it has been demonstrated that this type of immunity can protect mice from a lethal challenge with influenza A virus.<sup>32</sup>

### Candidate Proteins for a T-cell Vaccine for Influenza

Unlike surface glycoproteins, proteins located within the influenza virion such as the NP and M1 are highly conserved due to

their functional role during the viral replication cycle. It is well known that while they cannot induce neutralizing antibodies in infected or immunized animals, they are capable of inducing strong cellular immunity. For many years it has been known that mice recovering from infection with a certain subtype of influenza A virus have some protection against lethal challenge with a heterologous strain, and that the immunological basis of this phenomenon is mediated mainly by anti-influenza specific CTLs.<sup>33,34</sup> These CTLs recognize highly conserved amino acid sequences of certain viral proteins, mainly proteins within the virus particle, exposed by the MHC class I pathway on the surface of infected cell.<sup>35-38</sup> Although it has not been clearly established yet, there is some evidence of correlation between CTLs and protection, in humans.<sup>39,40</sup>

The cross-reactivity of polyclonal virus-specific CD8<sup>+</sup> T-cell populations (obtained from European subjects), which target cells pulsed with H5N1-derived peptides or NP gene-transfected cells of the same avian influenza virus, demonstrates that human CTL response displays a high degree of cross-reactivity for very diverse influenza virus subtypes.<sup>41</sup>

The concept that a vaccine formulated with a recombinant antigen unable to induce neutralizing antibodies can protect immunized mice from a lethal viral challenge was validated in the early 90s. Earlier experiences with a NP-based T-cell vaccine using purified recombinant NP (rNP) as a vaccine antigen indicated the validity of this concept,<sup>42</sup> which was further confirmed with a genetic vaccine containing a NP gene-carrying plasmid, which was able to protect mice against lethal challenges with an heterologous influenza virus.<sup>43</sup>

### Recombinant Vector Based T-cell Vaccine for Influenza

Very recently, the use of recombinant adenovirus vectors expressing viral proteins NP and M2 (full length or M2e), showed that a T-cell vaccine against influenza could be extremely effective in mice.<sup>44,45</sup> Furthermore, in a similar approach in a Phase I clinical trial, a modified Vaccinia virus Ankara (MVA) vector, encoding NP and M1, generated potent T-cell CD8<sup>+</sup> specific immunity in immunized humans.<sup>46</sup> A Phase II clinical trial, conducted in healthy volunteers showed the efficacy of this vaccine to protect against flu symptoms after a challenge with live virus.<sup>47</sup>

### Development of a T-cell Vaccine Based on Adjuvanted rNP Produced in a Prokaryotic System

Although influenza vaccine candidates based on recombinant vectors are very promising, it should be noted that safety trials for this strategy will take a long time before they are approved and massively available in the market. Furthermore, its production involves the handling of sophisticated and expensive technology not available in many developing countries. Therefore, it would be important to develop vaccines able to produce the same results but using simpler and less expensive production systems. Recently published results suggest that a NP based T-cell vaccine against influenza A could also be achieved using the recombinant

protein produced in *E. coli*, which would be a far more simple and inexpensive system. In our laboratory, we have confirmed other group's results, that is that the NP protein can be easily produced and purified in large quantities at low cost in *E. coli*.<sup>48-50</sup> The same appears true for other influenza proteins which are also candidates for a T-cell vaccine, such as M1 and M2.<sup>50,51</sup>

The main limitation of this approach is the difficulty to induce a strong CTL response in animals immunized with an exogenous protein.<sup>51</sup> However, exogenous proteins may induce a CTLs response by the phenomenon known as cross presentation,<sup>52</sup> and it is known that cross-presentation of an exogenous protein can be greatly stimulated with certain adjuvants which favor this process.<sup>53</sup> Recently, several reports confirmed the effectiveness of vaccines formulated with adjuvanted rNP to protect vaccinated animals against a lethal challenge of homologous or heterologous virus. Intranasal administration of cholera toxin combined with rNP protected against multiple viral subtypes.<sup>49</sup> The combination of recombinant NP and M2 formulated as liposomes stimulated a marked increase of specific CTLs and protected the vaccinated mice from a lethal challenge with the H5N1 avian strain.<sup>50</sup> A vaccine formulated with rNP and a TLR3 ligand, induced specific CTLs and protection against lethal challenge from influenza virus.<sup>54</sup> Fortunately, the knowledge on the possibilities of increasing the CTL responses to a recombinant protein is constantly increasing. A priori, there are multiple potential formulations that could lead to the optimization of a T-cell based rNP vaccine for influenza. In the pursuit of such a strategy, our laboratory has recently begun a systematic search of adjuvants able to promote a strong CTL response in animals vaccinated with rNP.

### Iscomatrix Adjuvanted Influenza Vaccines

Iscomatrix (IMX) adjuvant is an immunostimulating system which also optimizes the process of antigen delivery, and is very efficient in obtaining a strong CTL response after immunization with exogenous protein.<sup>55,56</sup> IMX consists of nanoparticles of about 40–50 nm in diameter with a strong negative charge, generated by the self assembly of phospholipids, cholesterol and saponins.<sup>55</sup> The negative charge of these particles favors their interaction with basic proteins such as the NP.<sup>57</sup> After immunization, the nanoparticles containing the antigen migrate to the draining lymph nodes, where they are captured and internalized by lymphoid resident dendritic cells (DC). IMX favors the process of extracellular antigen translocation from the endosome to the cytosol for proteasomal degradation. The processed peptides can then enter the major histocompatibility complex class I (MHC I) pathway, favoring the mechanism of cross presentation and the generation of CD8+ lymphocytes. The DCs that have taken up the particles are also activated, releasing many cytokines and lymphokines which stimulate the magnitude of the immune response. On the other hand, this system also has a strong stimulating activity on the humoral arm of the immune response.<sup>56</sup> This system has been successful when combined with inactivated influenza vaccines. It has proven very effective in stimulating mucosal immunity by the intranasal route.<sup>58</sup>

It has also been effective in decreasing the minimum antigen dose required to obtain protection after pulmonary delivery of an influenza vaccine.<sup>59</sup> In mice, it was shown that IMX greatly improves the efficiency of a commercial vaccine increasing hetero-subtypic protection and CTL response.<sup>60</sup> In humans, a trivalent inactivated influenza vaccine formulated with IMX, elicited a sharp increase in the CTL response compared with those individuals that received the unadjuvanted vaccine.<sup>61,62</sup> Rimmelzwaan et al.<sup>62</sup> found that IMX significantly increases the anti-HA CTL response, but not an anti-NP CTL response. This is different from what happens in vivo, where after infection with influenza virus, the anti NP CTL response is dominant. In our experience, analysis of the values of IgG subtypes and interleukins in the sera of mice that had been immunized with IMX-formulated rNP clearly indicated that the response obtained had a strong Th1 profile.<sup>63</sup> These experiments also showed the generation of high titers of IgG anti-NP. This should be also taken into account, since it has been demonstrated that specific high titers obtained after immunization of mice with rNP contributed to a rapid antibody-dependent elimination of the year 2009 H1N1 pandemic virus strain and that high anti NP titers correlated with an increase in the CD8+ response.<sup>64,65</sup> These results strongly suggest that antibodies induced by immunization with rNP-IMX could also contribute, significantly, to a T-cell vaccine.

### Are Adjuvanted Split Virus Vaccines Able to Induce a T Cell Response?

As mentioned previously, Rimmelzwaan et al.<sup>62</sup> found that, contrary to what happens in infected individuals, the formulation of a split trivalent inactivated vaccine with IMX promotes the generation of CTL specific to HA but not NP. Lamere et al.<sup>64</sup> found that the lack of immunological reactivity of the endogenous NP contained in the split trivalent inactivated vaccine in mice, may be slightly improved by adding lipopolysaccharides to the vaccine formulation. In humans, preceding titers of specific anti NP IgG can be boosted in only few cases in subjects immunized with conventional trivalent vaccines. In a similar way, Savard et al.<sup>66</sup> found that NP and M1 proteins present in split virion seasonal flu vaccine, are not immunogenic in immunized mice. However they showed that immunization of mice and ferrets with the same vaccine adjuvanted with papaya mosaic virus nanoparticles triggered a cell-mediated immune response to NP and M1, and long-lasting protection in animals challenged with a heterosubtypic influenza strain. Based on the above mentioned facts, there is some evidence that the endogenous NP contained in split influenza vaccines can be stimulated to produce a CTL response. However, the current processes of vaccine manufacturing are not validated to assess the content of NP in each batch, nor is it certain that the NP complexed with the genomic RNA in whole inactivated virus will be the most suitable antigen. On this basis it is tempting to hypothesize that for the purpose of generating an influenza specific CTL response, it would be more convenient to use recombinant NP, combined with a seasonal subunit vaccine.

## Conclusions

In recent years the trend in the field of recombinant vaccines development has been the use of viral vectors when looking for a strong cellular response<sup>31</sup> and purified proteins when looking for a humoral response.<sup>67</sup> The use of purified recombinant proteins for the development of vaccines against infectious agents that require a strong cellular response has been virtually neglected. However, our results and those of other laboratories confirm that it is possible to induce cell-mediated immune responses with purified proteins formulated with the appropriate adjuvants. Such formulations may even be improved by using particulate delivery systems. This type of methodology has been developed extensively in recent years and has also proved to be a very powerful method of inducing cellular immunity.<sup>68-70</sup> In our

laboratory we are currently developing delivery systems which include rNP in adjuvant loaded nanoparticles. In our work we have used rNP alone, however it is clear that the inclusion of other proteins with similar properties such as M1 and M2 is desirable. The production of vaccines based on this technology would be inexpensive due to their simplicity, and the technology could be certainly implemented in developing countries, which are now almost completely dependent on external sources of production. A vaccine of this type should be combined with the seasonal vaccine to elicit both robust influenza-specific antibody and CTL responses for maximal protection.

## Disclosure of Potential Conflicts of Interest

The authors declare no conflict of interest.

## References

1. Osterhaus A, Fouchier R, Rimmelzwaan G. Towards universal influenza vaccines: Philos Trans R Soc Lond B Biol Sci 2011; 366:2766-73; PMID:21893539; <http://dx.doi.org/10.1098/rstb.2011.0102>.
2. Dormitzer PR, Tsai TF, Del Giudice G. New technologies for influenza vaccines. Hum Vaccin Immunother 2012; 8:45-58; PMID:22251994.
3. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:36-44; PMID:22032844; [http://dx.doi.org/10.1016/S1473-3099\(11\)70295-X](http://dx.doi.org/10.1016/S1473-3099(11)70295-X).
4. Quan FS, Compans RW, Kang SM. Oral vaccination with inactivated influenza vaccine induces cross-protective immunity. Vaccine 2012; 30:180-8; PMID:22107852; <http://dx.doi.org/10.1016/j.vaccine.2011.11.028>.
5. Okamoto S, Matsuoka S, Takenaka N, Haredy AM, Tanimoto T, Gomi Y, et al. Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection. Clin Vaccine Immunol 2012; 19:979-90; PMID:22552600; <http://dx.doi.org/10.1128/CVI.00016-12>.
6. Dhont PA, Albert A, Brenders P, Podwapińska A, Pollet A, Scheveneels D, et al. Acceptability of Intanza® 15 µg intradermal influenza vaccine in Belgium during the 2010-2011 influenza season. Adv Ther 2012; 29:562-77; PMID:22678831; <http://dx.doi.org/10.1007/s12325-012-0025-9>.
7. Kang SM, Song JM, Kim YC. Microneedle and mucosal delivery of influenza vaccines. Expert Rev Vaccines 2012; 11:547-60; PMID:22697052; <http://dx.doi.org/10.1586/erv.12.25>.
8. O'Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine 2012; 30:4341-8; PMID:22682289; <http://dx.doi.org/10.1016/j.vaccine.2011.09.061>.
9. Scheifele DW, Ward BJ, Dionne M, Vanderkooi OG, Loeb M, Coleman BL, et al.; PHAC/CIHR Influenza Research Network (PCIRN). Compatibility of ASO3-adjuvanted H1N1pdm09 and seasonal trivalent influenza vaccines in adults: results of a randomized, controlled trial. Vaccine 2012; 30:4728-32; PMID:22652402; <http://dx.doi.org/10.1016/j.vaccine.2012.05.029>.
10. Cox RJ, Pedersen G, Madhun AS, Svindland S, Sævik M, Breakwell L, et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine 2011; 29:8049-59; PMID:21864624; <http://dx.doi.org/10.1016/j.vaccine.2011.08.042>.
11. Budimir N, Huckriede A, Meijerhof T, Boon L, Gostick E, Price DA, et al. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity. PLoS One 2012; 7:e30898; PMID:22303469; <http://dx.doi.org/10.1371/journal.pone.0030898>.
12. Furuya Y, Regner M, Lobigs M, Koskinen A, Müllbacher A, Alsharif M. Effect of inactivation method on the cross-protective immunity induced by whole 'killed' influenza A viruses and commercial vaccine preparations. J Gen Virol 2010; 91:1450-60; PMID:20147516; <http://dx.doi.org/10.1099/vir.0.018168-0>.
13. Hessel A, Schwendinger M, Holzer GW, Orlinger KK, Coulibaly S, Savidis-Dacho H, et al. Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. PLoS One 2011; 6:e16247; PMID:21283631; <http://dx.doi.org/10.1371/journal.pone.0016247>.
14. Schwartz JA, Buonocore L, Suguitan A Jr., Hunter M, Marx PA, Subbarao K, et al. Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques. J Virol 2011; 85:4602-5; PMID:21325423; <http://dx.doi.org/10.1128/JVI.02491-10>.
15. Steitz J, Barlow PG, Hossain J, Kim E, Okada K, Kenniston T, et al. A candidate H1N1 pandemic influenza vaccine elicits protective immunity in mice. PLoS One 2010; 5:e10492; PMID:20463955; <http://dx.doi.org/10.1371/journal.pone.0010492>.
16. Hossain MJ, Bourgeois M, Quan FS, Lipatov AS, Song JM, Chen LM, et al. Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza. Clin Vaccine Immunol 2011; 18:2010-7; PMID:22030367; <http://dx.doi.org/10.1128/CVI.05206-11>.
17. Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011; 29:7733-9; PMID:21835220; <http://dx.doi.org/10.1016/j.vaccine.2011.07.128>.
18. Khurana S, Verma S, Verma N, Crevar CJ, Carter DM, Manischewitz J, et al. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets. J Virol 2011; 85:1246-56; PMID:21084473; <http://dx.doi.org/10.1128/JVI.02107-10>.
19. Taylor DN, Treanor JJ, Sheldon EA, Johnson C, Umlauf S, Song L, et al. Development of VAXI28, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine 2012; 30:5761-9; PMID:22796139; <http://dx.doi.org/10.1016/j.vaccine.2012.06.086>.
20. Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, Hendel CS, et al.; VRC 306 Study Team. DNA priming and influenza vaccine immunogenicity: two phase I open label randomised clinical trials. Lancet Infect Dis 2011; 11:916-24; PMID:21975270; [http://dx.doi.org/10.1016/S1473-3099\(11\)70240-7](http://dx.doi.org/10.1016/S1473-3099(11)70240-7).
21. Atsmon J, Kate-Ilovitz E, Shaikevich D, Singer Y, Volokhov I, Haim KY, et al. Safety and immunogenicity of multimeric-001—a novel universal influenza vaccine. J Clin Immunol 2012; 32:595-603; PMID:22318394; <http://dx.doi.org/10.1007/s10875-011-9632-5>.
22. Roose K, Fiers W, Saelens X. Pandemic preparedness: toward a universal influenza vaccine. Drug News Perspect 2009; 22:80-92; PMID:19330167; <http://dx.doi.org/10.1358/dnp.2009.22.2.1334451>.
23. Yewdell JW. Viva la revolución: rethinking influenza a virus antigenic drift. Curr Opin Virol 2011; 1:177-83; PMID:22034587; <http://dx.doi.org/10.1016/j.coviro.2011.05.005>.
24. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011; 333:850-6; PMID:21798894; <http://dx.doi.org/10.1126/science.1205669>.
25. Wang TT, Tan GS, Hai R, Pica N, Ngai L, Ekiert DC, et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A 2010; 107:18979-84; PMID:20956293; <http://dx.doi.org/10.1073/pnas.1013387107>.
26. Schorsart M, De Filette M, Fiers W, Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009; 8:499-508; PMID:19348565; <http://dx.doi.org/10.1586/erv.09.6>.
27. Shim BS, Choi YK, Yun CH, Lee EG, Jeon YS, Park SM, et al. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza. PLoS One 2011; 6:e27953; PMID:22140491; <http://dx.doi.org/10.1371/journal.pone.0027953>.
28. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 2011; 186:1022-31; PMID:21169548; <http://dx.doi.org/10.4049/jimmunol.0902147>.
29. Talbot HK, Rock MT, Johnson C, Tussey L, Kavita U, Shanker A, et al. Immunopotential of trivalent influenza vaccine when given with VAXI02, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin. PLoS One 2010; 5:e14442; PMID:21203437; <http://dx.doi.org/10.1371/journal.pone.0014442>.



30. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. *Vaccine* 2011; 29:5145-52; PMID:21624416; <http://dx.doi.org/10.1016/j.vaccine.2011.05.041>.
31. Gilbert SC. T-cell-inducing vaccines - what's the future. *Immunology* 2012; 135:19-26; PMID:22044118; <http://dx.doi.org/10.1111/j.1365-2567.2011.03517.x>.
32. Mbawuike IN, Zhang Y, Couch RB. Control of mucosal virus infection by influenza nucleoprotein-specific CD8+ cytotoxic T lymphocytes. *Respir Res* 2007; 8:44; PMID:17597533; <http://dx.doi.org/10.1186/1465-9921-8-44>.
33. Effros RB, Doherty PC, Gerhard W, Bennink J. Generation of both cross-reactive and virus-specific T-cell populations after immunization with serologically distinct influenza A viruses. *J Exp Med* 1977; 145:557-68; PMID:233901; <http://dx.doi.org/10.1084/jem.145.3.557>.
34. Yap KL, Ada GL, McKenzie IF. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. *Nature* 1978; 273:238-9; PMID:306072; <http://dx.doi.org/10.1038/273238a0>.
35. Wraith DC, Askonas BA. Induction of influenza A virus cross-reactive cytotoxic T cells by a nucleoprotein/haemagglutinin preparation. *J Gen Virol* 1985; 66:1327-31; PMID:3874261; <http://dx.doi.org/10.1099/0022-1317-66-6-1327>.
36. Hurwitz JL, Hackett CJ, McAndrew EC, Gerhard W. Murine TH response to influenza virus: recognition of hemagglutinin, neuraminidase, matrix, and nucleoproteins. *J Immunol* 1985; 134:1994-8; PMID:3155776.
37. Yewdell JW, Bennink JR, Smith GL, Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. *Proc Natl Acad Sci U S A* 1985; 82:1785-9; PMID:3872457; <http://dx.doi.org/10.1073/pnas.82.6.1785>.
38. Taylor PM, Askonas BA. Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. *Immunology* 1986; 58:417-20; PMID:2426185.
39. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. *N Engl J Med* 1983; 309:13-7; PMID:6602294; <http://dx.doi.org/10.1056/NEJM198307073090103>.
40. Epstein SL. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. *J Infect Dis* 2006; 193:49-53; PMID:16323131; <http://dx.doi.org/10.1086/498980>.
41. Kreijtz JH, de Mutsert G, van Baalen CA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. *J Virol* 2008; 82:5161-6; PMID:18353950; <http://dx.doi.org/10.1128/JVI.02694-07>.
42. Tite JP, Hughes-Jenkins C, O'Callaghan D, Dougan G, Russell SM, Gao XM, et al. Anti-viral immunity induced by recombinant nucleoprotein of influenza A virus. II. Protection from influenza infection and mechanism of protection. *Immunology* 1990; 71:202-7; PMID:2172156.
43. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dworki VJ, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. *Science* 1993; 259:1745-9; PMID:8456302; <http://dx.doi.org/10.1126/science.8456302>.
44. Price GE, Soboleski MR, Lo CY, Misplon JA, Quirion MR, Houser KV, et al. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. *PLoS One* 2010; 5:e13162; PMID:20976273; <http://dx.doi.org/10.1371/journal.pone.0013162>.
45. Zhou D, Wu TL, Lasaro MO, Latimer BP, Parzych EM, Bian A, et al. A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge. *Mol Ther* 2010; 18:2182-9; PMID:20877342; <http://dx.doi.org/10.1038/mt.2010.202>.
46. Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. *Clin Infect Dis* 2011; 52:1-7; PMID:21148512; <http://dx.doi.org/10.1093/cid/ciq015>.
47. Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. *Clin Infect Dis* 2012; 55:19-25; PMID:22441650; <http://dx.doi.org/10.1093/cid/cis327>.
48. Ye Q, Krug RM, Tao YJ. The mechanism by which influenza A virus nucleoprotein forms oligomers and binds RNA. *Nature* 2006; 444:1078-82; PMID:17151603; <http://dx.doi.org/10.1038/nature05379>.
49. Guo L, Zheng M, Ding Y, Li D, Yang Z, Wang H, et al. Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein. *Arch Virol* 2010; 155:1765-75; PMID:20652335; <http://dx.doi.org/10.1007/s00705-010-0756-3>.
50. Thueng-in K, Maneewatch S, Srimanote P, Songserm T, Tapchaisri P, Sookkrung N, et al. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines. *Vaccine* 2010; 28:6765-77; PMID:20688037; <http://dx.doi.org/10.1016/j.vaccine.2010.07.065>.
51. Ebrahimi SM, Tebianian M, Aghaiypour K, Nili H, Mirjalili A. Prokaryotic expression and characterization of avian influenza A virus M2 gene as a candidate for universal recombinant vaccine against influenza A subtypes; specially H5N1 and H9N2. *Mol Biol Rep* 2010; 37:2909-14; PMID:19809890; <http://dx.doi.org/10.1007/s11033-009-9851-5>.
52. Neeffes J, Sadaka C. Into the intracellular logistics of cross-presentation. *Front Immunol* 2012; 3:31; PMID:22566915; <http://dx.doi.org/10.3389/fimmu.2012.00031>.
53. Dresch C, Leverrier Y, Marvel J, Shortman K. Development of antigen cross-presentation capacity in dendritic cells. *Trends Immunol* 2012; 33:381-8; PMID:22677187; <http://dx.doi.org/10.1016/j.it.2012.04.009>.
54. Jelinek I, Leonard JN, Price GE, Brown KN, Meyer-Manlapat A, Goldsmith PK, et al. TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. *J Immunol* 2011; 186:2422-9; PMID:21242525; <http://dx.doi.org/10.4049/jimmunol.1002845>.
55. Wilson NS, Yang B, Morelli AB, Koernig S, Yang A, Loeser S, et al. ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway. *Immunol Cell Biol* 2012; 90:540-52; PMID:21894173; <http://dx.doi.org/10.1038/icb.2011.71>.
56. Morelli AB, Becher D, Koernig S, Silva A, Drane D, Maraskovsky E. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. *J Med Microbiol* 2012; 61:935-43; PMID:22442293; <http://dx.doi.org/10.1099/jmm.0.040857-0>.
57. McBurney WT, Lendemes DG, Myschik J, Hennessy T, Rades T, Hook S. In vivo activity of cationic immune stimulating complexes (PLUSCOMs). *Vaccine* 2008; 26:4549-56; PMID:18585421; <http://dx.doi.org/10.1016/j.vaccine.2008.06.024>.
58. Coulter A, Harris R, Davis R, Drane D, Cox J, Ryan D, et al. Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine. *Vaccine* 2003; 21:946-9; PMID:12547607; [http://dx.doi.org/10.1016/S0264-410X\(02\)00545-5](http://dx.doi.org/10.1016/S0264-410X(02)00545-5).
59. Wee JL, Scheerlinck JP, Snibson KJ, Edwards S, Pearce M, Quinn C, et al. Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing. *Mucosal Immunol* 2008; 1:489-96; PMID:19079216; <http://dx.doi.org/10.1038/mi.2008.59>.
60. Sambhara S, Kurichh A, Miranda R, Tumpey T, Rowe T, Renshaw M, et al. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. *Cell Immunol* 2001; 211:143-53; PMID:11591118; <http://dx.doi.org/10.1006/cimm.2001.1835>.
61. Ennis FA, Cruz J, Jameson J, Klein M, Burt D, Thippahawong J. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). *Virology* 1999; 259:256-61; PMID:10388649; <http://dx.doi.org/10.1006/viro.1999.9765>.
62. Rimmelzwaan GF, Nieuwkoop N, Brandenburg A, Sutter G, Beyer WE, Maher D, et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. *Vaccine* 2000; 19:1180-7; PMID:11137255; [http://dx.doi.org/10.1016/S0264-410X\(00\)00310-8](http://dx.doi.org/10.1016/S0264-410X(00)00310-8).
63. Cargnelutti DE, Sanchez MV, Alvarez P, Boado L, Glikmann G, Mattion N, et al. Improved immune response to recombinant influenza nucleoprotein formulated with ISCOMATRIX. *J Microbiol Biotechnol* 2012; 22:416-21; PMID:22450799; <http://dx.doi.org/10.4014/jmb.1106.06021>.
64. Lamere MW, Moquin A, Lee FE, Misra RS, Blair PJ, Haynes L, et al. Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. *J Virol* 2011; 85:5027-35; PMID:21367900; <http://dx.doi.org/10.1128/JVI.00150-11>.
65. LaMere MW, Lam HT, Moquin A, Haynes L, Lund FE, Randall TD, et al. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. *J Immunol* 2011; 186:4331-9; PMID:21357542; <http://dx.doi.org/10.4049/jimmunol.1003057>.
66. Savard C, Guérin A, Drouin K, Bolduc M, Labiberté-Gagné ME, Dumas MC, et al. Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles. *PLoS One* 2011; 6:e21522; PMID:21747909; <http://dx.doi.org/10.1371/journal.pone.0021522>.
67. Duthie MS, Raman VS, Piazza FM, Reed SG. The development and clinical evaluation of second-generation leishmaniasis vaccines. *Vaccine* 2012; 30:134-41; PMID:22085553; <http://dx.doi.org/10.1016/j.vaccine.2011.11.005>.
68. Tacken PJ, Zeelenberg IS, Cruz LJ, van Hout-Kuijper MA, van de Griend G, Fokkink RG, et al. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvant activity. *Blood* 2011; 118:6836-44; PMID:21967977; <http://dx.doi.org/10.1182/blood-2011-07-367615>.
69. Nembrini C, Stano A, Dane KY, Ballester M, van der Vlies AJ, Marsland BJ, et al. Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. *Proc Natl Acad Sci U S A* 2011; 108:E989-97; PMID:21969597; <http://dx.doi.org/10.1073/pnas.1104264108>.
70. Foged C, Hansen J, Agger EM. License to kill: Formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems. *Eur J Pharm Sci* 2012; 45:482-91; PMID:21888971; <http://dx.doi.org/10.1016/j.ejps.2011.08.016>.